OptimizeRx annual r&d spending
2018
2019
2020
2024
2025
OptimizeRx R&D Spending Growth & History (OPRX)
OptimizeRx's r&d spending was $0 for fiscal 2025.
View full OptimizeRx company overviewOptimizeRx annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | — | — |
| 2020 | 2020-12-31 | $0 | −$1.6M | — |
| 2019 | 2019-12-31 | $1.6M | $1.6M | — |
| 2018 | 2018-12-31 | $0 | — | — |
OptimizeRx quarterly r&d spending
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.3M | $182,000 | +5.89% |
| Q1 2026 | 2026-03-31 | $3.4M | $150,000 | +4.61% |
| Q2 2025 | 2025-06-30 | $3.1M | — | — |
| Q1 2025 | 2025-03-31 | $3.3M | — | — |
OptimizeRx r&d spending trends
Over the last five fiscal years, OptimizeRx's r&d spending increased from $0 to $0, a change of $0. The latest reported quarter, Q2 2026, shows $3.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review OptimizeRx source filings ↗